Roche and its Genentech unit today announced the groundbreaking for its newest U.S. manufacturing site in Holly Springs, North Carolina. Genentech said the development marks the establishment of its first manufacturing facility on the East Coast. It designed the 65,000-square-meter facility to support the production of its future portfolio of metabolic medicines. Those include next-generation… The post Roche’s Genentech breaks ground on U.S. manufacturing facility appeared first on Pharma...| Pharmaceutical Processing World
CANNES – The promise of AI-powered creative versioning and real-time optimization in healthcare marketing faces a fundamental obstacle: regulatory review processes that haven�...| Beet.TV - The Root to the Media Revolution
One of America’s premier research institutions ends an academic year with both of its top leadership positions in question, waiting on an unprecedented misconduct investigation into the University’s own president.| The Stanford Daily
An email contained additional allegations about Marc Tessier-Lavigne’s Alzheimer’s research and the 2011 internal review that former colleagues allege uncovered falsification.| The Stanford Daily
His paper was called “the miracle result.” But it never turned into an Alzheimer’s treatment. Now, four former Genentech senior scientists and executives allege that an internal review in 2011 discovered the paper had been based on fabricated research — and that Marc Tessier-Lavigne kept the results of the review from becoming public. He denies the allegations.| The Stanford Daily
Marc Tessier-Lavigne faces years of allegations of scientific misconduct in his research, including papers he co-authored containing images which researchers say appear “definitely photoshopped.” One of them is now under investigation by a major journal.| The Stanford Daily